Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption.

Sutton SC, Nause R, Gandelman K.

AAPS J. 2017 Jul;19(4):1084-1090. doi: 10.1208/s12248-017-0065-9. Epub 2017 Mar 20.

PMID:
28321831
2.

Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.

Gandelman K, Lamson M, Salageanu J, Bramson C, Matschke K, Malhotra B.

Clin Pharmacol Drug Dev. 2015 Sep;4(5):370-6. doi: 10.1002/cpdd.177. Epub 2015 Jan 22.

PMID:
27137146
3.

Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edema.

Basile AS, Hutmacher MM, Kowalski KG, Gandelman KY, Nickens DJ.

Clin Ophthalmol. 2015 Feb 16;9:323-35. doi: 10.2147/OPTH.S74050. eCollection 2015.

4.

Population pharmacokinetics of atorvastatin and its active metabolites in children and adolescents with heterozygous familial hypercholesterolemia: selective use of informative prior distributions from adults.

Knebel W, Gastonguay MR, Malhotra B, El-Tahtawy A, Jen F, Gandelman K.

J Clin Pharmacol. 2013 May;53(5):505-16. doi: 10.1002/jcph.66. Epub 2013 Feb 4.

PMID:
23381936
5.

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.

Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K.

Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x.

6.

Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Malhotra B, Alvey C, Gong J, Li X, Duczynski G, Gandelman K.

Br J Clin Pharmacol. 2011 Aug;72(2):257-62. doi: 10.1111/j.1365-2125.2011.03989.x.

7.

An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia.

Gandelman K, Glue P, Laskey R, Jones J, LaBadie R, Ose L.

Pediatr Cardiol. 2011 Apr;32(4):433-41. doi: 10.1007/s00246-011-9885-z. Epub 2011 Jan 23.

8.

Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies.

Gandelman K, Fung GL, Messig M, Laskey R.

Am J Ther. 2012 May;19(3):164-73. doi: 10.1097/MJT.0b013e3181f28fb5.

PMID:
20975528
9.

Thorough QT study of the effect of fesoterodine on cardiac repolarization.

Malhotra B, Wood N, Sachse R, Gandelman K.

Int J Clin Pharmacol Ther. 2010 May;48(5):309-18.

PMID:
20420787
10.

Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.

Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K, Obach RS, Damle B.

J Clin Pharmacol. 2011 Feb;51(2):229-36. doi: 10.1177/0091270010366445. Epub 2010 Apr 6.

PMID:
20371736
11.

The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.

Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC.

Curr Med Chem. 2009;16(33):4481-9. Review.

PMID:
19835561
12.

Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine.

Malhotra B, Gandelman K, Sachse R, Wood N.

J Clin Pharmacol. 2009 Apr;49(4):477-82. doi: 10.1177/0091270009332434. Epub 2009 Feb 26.

PMID:
19246724
13.

The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial.

Gandelman K, Alderman JA, Glue P, Lombardo I, LaBadie RR, Versavel M, Preskorn SH.

J Clin Psychiatry. 2009 Jan;70(1):58-62. Epub 2008 Oct 21.

PMID:
19026256
14.

Pharmacokinetic profile of fesoterodine.

Malhotra B, Guan Z, Wood N, Gandelman K.

Int J Clin Pharmacol Ther. 2008 Nov;46(11):556-63.

PMID:
19000553
15.
16.

Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.

Liu P, Foster G, Gandelman K, LaBadie RR, Allison MJ, Gutierrez MJ, Sharma A.

Antimicrob Agents Chemother. 2007 Oct;51(10):3617-26. Epub 2007 Jul 23.

17.
18.

Molecular definition of the smallest region of deletion overlap in the Wolf-Hirschhorn syndrome.

Gandelman KY, Gibson L, Meyn MS, Yang-Feng TL.

Am J Hum Genet. 1992 Sep;51(3):571-8.

19.

Dopamine D2 receptor subtypes couple to different second messenger systems.

Todd RD, Mack KJ, Gandelman KY, Hickok JM, O'Malley KL.

Neurochem Int. 1992 Mar;20 Suppl:23S-26S. Review. No abstract available.

PMID:
1365431
20.

Analysis of the structure and expression of the human dopamine D2A receptor gene.

Gandelman KY, Harmon S, Todd RD, O'Malley KL.

J Neurochem. 1991 Mar;56(3):1024-9.

PMID:
1825222
21.

Species and regional differences in the expression of cell-type specific elements at the human and rat tyrosine hydroxylase gene loci.

Gandelman KY, Coker GT 3rd, Moffat M, O'Malley KL.

J Neurochem. 1990 Dec;55(6):2149-52.

PMID:
1977891
22.

Organization and expression of the rat D2A receptor gene: identification of alternative transcripts and a variant donor splice site.

O'Malley KL, Mack KJ, Gandelman KY, Todd RD.

Biochemistry. 1990 Feb 13;29(6):1367-71.

PMID:
2139794

Supplemental Content

Loading ...
Support Center